"Glucometrics"--assessing the quality of inpatient glucose management.

Abstract:

BACKGROUND:For patients with diabetes, the quality of outpatient glycemic control is readily assessed by hemoglobin A1c. In contrast, standardized measures for assessing the quality of blood glucose (BG) management in hospitalized patients are lacking. Because of recent studies demonstrating the benefits of strict glycemic control in critically ill patients, hospitals nationwide are dedicating resources to address this important issue. To facilitate advances in this nascent field, standardized metrics for inpatient glycemic control should be developed and validated. METHODS:We used 1 month of fingerstick BG levels from a general hospital ward to develop and test three analytic models, based on three units of inpatient BG analysis: population (i.e., ward), patient-day, and patient. To assess the effect of the source of blood samples, we repeated these analyses after adding venous plasma glucose levels. Finally, we employed an idealized intensive care unit data set to establish "gold standard" metrics for inpatient glycemic control. RESULTS:Mean and median BG levels and the proportion of BG levels within an "optimal" range (80-139 mg/dL) were similar among the three models, whereas hypoglycemic and hyperglycemic event rates varied considerably. Inclusion of venous glucose levels did not substantially affect the results. Of the three models tested, the patient-day model appears to most faithfully reflect the quality of inpatient glycemic control. Achieving 85% of BG levels within optimal range may be considered gold standard. CONCLUSIONS:If validated elsewhere, these "glucometrics" would permit objective comparisons of inpatient glycemic control among hospitals and patient care units, and would allow institutions to gauge the success of their quality improvement initiatives.

journal_name

Diabetes Technol Ther

authors

Goldberg PA,Bozzo JE,Thomas PG,Mesmer MM,Sakharova OV,Radford MJ,Inzucchi SE

doi

10.1089/dia.2006.8.560

subject

Has Abstract

pub_date

2006-10-01 00:00:00

pages

560-9

issue

5

eissn

1520-9156

issn

1557-8593

journal_volume

8

pub_type

杂志文章
  • Continuous glucose monitoring reveals delayed nocturnal hypoglycemia after intermittent high-intensity exercise in nontrained patients with type 1 diabetes.

    abstract:OBJECTIVE:Exercise is a cornerstone of diabetes therapy in type 1 diabetes mellitus (DMT1) patients. The type of exercise is important in determining the propensity to hypoglycemia. We assessed, by continuous glucose monitoring (CGM), the glucose profiles during and in the following 20h after a session of two different...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1089/dia.2010.0038

    authors: Maran A,Pavan P,Bonsembiante B,Brugin E,Ermolao A,Avogaro A,Zaccaria M

    更新日期:2010-10-01 00:00:00

  • Comparison of Second-Generation Basal Insulin Analogs: A Review of the Evidence from Continuous Glucose Monitoring.

    abstract::Many people with insulin-treated diabetes continue to experience inadequate glycemic control and a high incidence of hypoglycemic events, despite improvements in therapeutic strategies. While glycated hemoglobin (HbA1c) is currently recognized as the gold-standard for assessing glycemic control, the measure reflects m...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2020.0180

    authors: Battelino T,Edelman SV,Nishimura R,Bergenstal RM

    更新日期:2021-01-01 00:00:00

  • Active assistance technology reduces glycosylated hemoglobin and weight in individuals with type 2 diabetes: results of a theory-based randomized trial.

    abstract:BACKGROUND:Type 2 diabetes is an individual health challenge requiring ongoing self-management. Remote patient reporting of relevant health parameters and linked automated feedback via mobile telephone have potential to strengthen self-management and improve outcomes. This research involved development and evaluation o...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2013.0056

    authors: Orsama AL,Lähteenmäki J,Harno K,Kulju M,Wintergerst E,Schachner H,Stenger P,Leppänen J,Kaijanranta H,Salaspuro V,Fisher WA

    更新日期:2013-08-01 00:00:00

  • Evaluation of the Adherence to Continuous Glucose Monitoring in the Management of Type 1 Diabetes Patients on Sensor-Augmented Pump Therapy: The SENLOCOR Study.

    abstract:BACKGROUND:Continuous glucose monitoring (CGM) and sensor-augmented pump (SAP) therapy improve glucose control provided good adherence. In France, not only diabetologists, nurses, and dieticians but also nurses employed by homecare providers (HCPNs) are together involved in the initiation and/or follow-up of continuous...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2015.0240

    authors: Picard S,Hanaire H,Baillot-Rudoni S,Gilbert-Bonnemaison E,Not D,Reznik Y,Guerci B

    更新日期:2016-03-01 00:00:00

  • Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.

    abstract::Type 2 diabetes is thought to develop as a result of progressive beta-cell dysfunction in the setting of insulin resistance, leading to increased risks of microvascular and macrovascular complications. Type 2 diabetes is currently treated with diet and exercise, followed by oral drug therapy, and finally exogenous ins...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2006.8.385

    authors: Kendall DM,Kim D,Maggs D

    更新日期:2006-06-01 00:00:00

  • Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours.

    abstract:BACKGROUND:This study assessed the feasibility of a portable bihormonal closed-loop system at home. SUBJECTS AND METHODS:Sixteen pump-treated patients with type 1 diabetes received 48 h of closed-loop therapy with a telemonitored insulin- and glucagon-delivering closed-loop system and 48 h of patient-managed open-loop...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2013.0166

    authors: van Bon AC,Luijf YM,Koebrugge R,Koops R,Hoekstra JB,DeVries JH

    更新日期:2014-03-01 00:00:00

  • Physiological and therapeutic roles of peroxisome proliferator-activated receptors.

    abstract::The peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor isoforms, including PPARgamma, PPARalpha, and PPARdelta, encoded by different genes. PPARs are ligand-regulated transcription factors that control gene expression by binding to specific response elements (PPREs) within promoters. P...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/15209150260007381

    authors: Berger J,Wagner JA

    更新日期:2002-01-01 00:00:00

  • Inaccurate Glucose Sensor Values After Hydroxyurea Administration.

    abstract:: Objective: To assess the degree, duration, mean absolute relative difference (MARD), and error analysis of discrepant values per continuous glucose monitoring (CGM) systems after hydroxyurea (HU) administration. Research Design and Methods: ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2020.0490

    authors: Tellez SE,Hornung LN,Courter JD,Abu-El-Haija M,Nathan JD,Lawson SA,Elder DA

    更新日期:2020-12-30 00:00:00

  • Continuous Glucose Monitoring, Glycemic Variability, and Excessive Fetal Growth in Pregnancies Complicated by Type 1 Diabetes.

    abstract:BACKGROUND:To examine trimester-specific associations among glycemic variability, fetal growth, and birthweight in pregnancies with type 1 diabetes mellitus (Type 1 DM). METHODS:In this retrospective cohort study of 41 pregnant women with Type 1 DM, we used continuous glucose monitoring (CGM) data to calculate glycemi...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2017.0443

    authors: Mulla BM,Noor N,James-Todd T,Isganaitis E,Takoudes TC,Curran A,Warren CE,O'Brien KE,Brown FM

    更新日期:2018-06-01 00:00:00

  • Can continuous subcutaneous insulin infusion improve health-related quality of life in patients with Shwachman-Bodian-Diamond syndrome and diabetes?

    abstract::We report the first case of the use of continuous subcutaneous insulin infusion (CSII) in a patient with Shwachman-Bodian-Diamond syndrome (SBDS) and diabetes. An Italian boy received diagnosis of SBDS at the age of 7 months (SBDS gene mutation: c.183-184TA → CT and c.258 + 2 T → C in compound heterozygous). The patie...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2014.0184

    authors: Terlizzi V,Zito E,Mozzillo E,Raia V,Franzese A

    更新日期:2015-01-01 00:00:00

  • Resistance to Data Loss of Glycemic Variability Measurements in Long-Term Continuous Glucose Monitoring.

    abstract:: Background: Continuous glucose monitoring (CGM) is a method of estimating blood glucose values from those recorded in the interstitial fluid. Because increasingly longer CGM measurements are possible, errors and data loss become more and more likely and potentially more da...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0247

    authors: Kucharski P,Pagacz K,Szadkowska A,Młynarski W,Romanowski A,Fendler W

    更新日期:2018-12-01 00:00:00

  • Biochemical stabilization of glucagon at alkaline pH.

    abstract:BACKGROUND:For patients with type 1 diabetes mellitus, a bihormonal artificial endocrine pancreas system utilizing glucagon and insulin has been found to stabilize glycemic control. However, commercially available formulations of glucagon cannot currently be used in such systems because of physical instability characte...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2014.0047

    authors: Caputo N,Jackson MA,Castle JR,El Youssef J,Bakhtiani PA,Bergstrom CP,Carroll JM,Breen ME,Leonard GL,David LL,Roberts CT Jr,Ward WK

    更新日期:2014-11-01 00:00:00

  • A new imaging and data transmitting device for telemonitoring of diabetic foot syndrome patients.

    abstract:BACKGROUND:Proper healing of ulcers and wounds on the feet of diabetes patients is important in order to prevent amputation. If the wound area reduction during the first 4 weeks of the treatment is not 40% or more, reevaluation of the treatment is necessary. The wound area evaluation is not complicated when the patient...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0004

    authors: Foltynski P,Ladyzynski P,Migalska-Musial K,Sabalinska S,Ciechanowska A,Wojcicki J

    更新日期:2011-08-01 00:00:00

  • Advanced meter features improve postprandial and paired self-monitoring of blood glucose in individuals with diabetes: results of the Actions with the CONTOUR Blood Glucose Meter and Behaviors in Frequent Testers (ACT) study.

    abstract:BACKGROUND:This study evaluated whether education and use of the advanced meter features of the CONTOUR(®) (Bayer HealthCare LLC, Diabetes Care, Tarrytown, NY) blood glucose monitoring system (BGMS) affect the frequency and pattern of blood glucose testing in insulin-using subjects with diabetes who routinely perform s...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2012.0051

    authors: Bergenstal RM,Bode BW,Tamler R,Trence DL,Stenger P,Schachner HC,Fullam J,Pardo S,Kohut T,Fisher WA

    更新日期:2012-10-01 00:00:00

  • Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.

    abstract:BACKGROUND:Currently, it is still unknown whether differences in glycemic control have any effect on glucose and insulin kinetics after vildagliptin administration. The aim of this study was to evaluate the effect of vildagliptin on glucose and insulin concentrations during a 24-h period in type 2 diabetes patients wit...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2013.0020

    authors: González-Ortiz M,Sánchez-Peña MJ,González-Ortiz LJ,Robles-Cervantes JA,García-Ortega YE,Gómez-Gaitán EA,Pérez-Rubio KG,Martínez-Abundis E

    更新日期:2013-07-01 00:00:00

  • Clinical trial of a noninvasive contact lens glucose sensor.

    abstract:OBJECTIVE:The purpose of the present study was to determine the effectiveness of a fluorescent contact lens glucose sensor in monitoring glucose in patients with diabetes. METHODS:Under an institutional review board-approved protocol, five fasting patients with type II diabetes were given a challenge consisting of 75 ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/dia.2004.6.782

    authors: March WF,Mueller A,Herbrechtsmeier P

    更新日期:2004-12-01 00:00:00

  • Evaluating the accuracy, reliability, and clinical applicability of continuous glucose monitoring (CGM): Is CGM ready for real time?

    abstract:BACKGROUND:This study was designed to assess the accuracy, reliability, and contribution to clinical decision-making of two commercially available continuous glucose monitoring (CGM) devices using a novel analytical approach. STUDY DESIGN:Eleven individuals with type 1 diabetes and five with type 2 diabetes wore a Gua...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2008.0041

    authors: Mazze RS,Strock E,Borgman S,Wesley D,Stout P,Racchini J

    更新日期:2009-01-01 00:00:00

  • Predicting the effectiveness of insulin pump therapy on glycemic control in clinical practice: a retrospective study of patients with type 1 diabetes from 10 outpatient diabetes clinics in Sweden over 5 years.

    abstract:BACKGROUND:Multicenter long-term studies of predictors for the effectiveness of continuous subcutaneous insulin infusion (CSII) in clinical practice are lacking. We hypothesized that there are substantially greater reductions in hemoglobin A1c (HbA1c) in patients with poor glycemic control and that other predictors may...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2014.0139

    authors: Clements M,Matuleviciene V,Attvall S,Ekelund M,Pivodic A,Dahlqvist S,Fahlén M,Haraldsson B,Lind M

    更新日期:2015-01-01 00:00:00

  • Glucose variability indices in type 1 diabetes: parsimonious set of indices revealed by sparse principal component analysis.

    abstract:BACKGROUND:Continuous glucose monitoring (CGM) time-series are often analyzed, retrospectively, to investigate glucose variability (GV), a risk factor for the development of complications in type 1 diabetes (T1D). In the literature, several tens of different indices for GV quantification have been proposed, but many of...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1089/dia.2013.0252

    authors: Fabris C,Facchinetti A,Sparacino G,Zanon M,Guerra S,Maran A,Cobelli C

    更新日期:2014-10-01 00:00:00

  • Area of the diabetic ulcers estimated applying a foot scanner-based home telecare system and three reference methods.

    abstract:BACKGROUND:Diabetic foot ulcer area is a basic parameter used for monitoring the wound healing and effectiveness of the treatment applied. TeleDiaFoS (developed earlier in collaboration with the Department and Clinic of Gastroenterology and Metabolic Diseases, Medical University of Warsaw, Warsaw, Poland) is one of jus...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0082

    authors: Ladyzynski P,Foltynski P,Molik M,Tarwacka J,Migalska-Musial K,Mlynarczuk M,Wojcicki JM,Krzymien J,Karnafel W

    更新日期:2011-11-01 00:00:00

  • Human factors research applied: the development of a personal touch screen insulin pump and users' perceptions of actual use.

    abstract:BACKGROUND:A brief history of the field of human factors research is covered, along with how this discipline is leveraged within medical device companies, to eliminate design flaws in products, in order to make them safe and effective for human use. The way in which human factors research was used to develop the t:slim...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2013.0098

    authors: Schaeffer NE

    更新日期:2013-10-01 00:00:00

  • Recovery of β-cell functions with low-dose insulin therapy: study in newly diagnosed type 2 diabetes mellitus patients.

    abstract:AIM:Insulin therapy induces remission in subjects with newly diagnosed type 2 diabetes mellitus (T2DM). This study assessed the insulin and C-peptide levels in newly diagnosed T2DM subjects during low-dose insulin therapy. SUBJECTS AND METHODS:Twenty newly diagnosed, drug-naive, T2DM patients without acute or chronic ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2010.0187

    authors: Bhattacharya S,Ammini AC,Jyotsna V,Gupta N,Dwivedi S

    更新日期:2011-04-01 00:00:00

  • Waist circumference identifies primary school children with metabolic syndrome abnormalities.

    abstract:OBJECTIVE:This study was designed to assess whether waist circumference can predict metabolic syndrome abnormalities in primary schoolchildren. RESEARCH DESIGN AND METHODS:Of 5,103 children (2,526 males) 4-13 years old who underwent anthropometric measurements, 530 had more extensive testing. Body mass index (BMI), wa...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2006.0017

    authors: Hirschler V,Maccallini G,Calcagno M,Aranda C,Jadzinsky M

    更新日期:2007-04-01 00:00:00

  • Chat line for adolescents with type 1 diabetes: a useful tool to improve coping with diabetes: a 2-year follow-up study.

    abstract:BACKGROUND:We evaluated the impact of a 2-year chat line involving adolescents with type 1 diabetes regarding quality of life and metabolic control. METHODS:We enrolled 193 children, 10-18 years of age (mean ± SD, 13.6 ± 2.7 years), with type 1 diabetes for 1.2-6 years (3.6 ± 2.4 years), body mass index of 23.2 ± 4.1 ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2010.0188

    authors: Iafusco D,Galderisi A,Nocerino I,Cocca A,Zuccotti G,Prisco F,Scaramuzza A

    更新日期:2011-05-01 00:00:00

  • A dynamic risk measure from continuous glucose monitoring data.

    abstract:BACKGROUND:The quantitative analysis of glucose time-series can greatly help the management of diabetes. In particular, a static nonlinear transformation, which symmetrizes the distribution of glucose levels by bringing them in the so-called risk space, was proposed previously for both self-monitoring blood glucose and...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0006

    authors: Guerra S,Sparacino G,Facchinetti A,Schiavon M,Man CD,Cobelli C

    更新日期:2011-08-01 00:00:00

  • Continuous glucose monitoring health outcomes.

    abstract::Continuous glucose monitoring (CGM) is a new tool that has recently become available to people with diabetes. Properly designing and conducting trials in order to answer important questions regarding the clinical usefulness of CGM is very difficult and fraught with many confounding variables and unique challenges. Ini...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0012

    authors: Edelman SV,Bailey TS

    更新日期:2009-06-01 00:00:00

  • An intelligent diabetes software prototype: predicting blood glucose levels and recommending regimen changes.

    abstract::Maintaining optimal blood glucose (BG) control is difficult for type 1 diabetes mellitus (T1DM) patients when typical daily regimens of food, insulin and exercise are altered. Artificial intelligence (AI) systems consisting of treatment algorithms calibrated through large datasets of patient specific information may o...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/15209150050501989

    authors: Otto E,Semotok C,Andrysek J,Basir O

    更新日期:2000-01-01 00:00:00

  • Assessment of a new insulin preparation for implanted pumps used in the treatment of type 1 diabetes.

    abstract:BACKGROUND:Implanted insulin pumps using the peritoneal route provide long-term improvement of glucose control compared with subcutaneous insulin therapy in type 1 diabetes (T1D) patients. The stability of insulin preparation is critical for a safe use in implanted pumps. Insuman implantable(®) (400 IU/mL) (Sanofi-Aven...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2013.0369

    authors: Schaepelynck P,Riveline JP,Renard E,Hanaire H,Guerci B,Baillot-Rudoni S,Sola-Gazagnes A,Catargi B,Fontaine P,Millot L,Martin JF,Tachouaft H,Jeandidier N,EVADIAC Group.

    更新日期:2014-09-01 00:00:00

  • A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System.

    abstract:OBJECTIVE:To evaluate the safety and effectiveness of the Loop Do-It-Yourself (DIY) automated insulin delivery system. RESEARCH DESIGN AND METHODS:A prospective real-world observational study was conducted, which included 558 adults and children (age range 1 to 71 years, mean HbA1c 6.8±1.0%) who initiated Loop either ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2020.0535

    authors: Lum J,Bailey R,Barnes-Lomen V,Naranjo D,Hood K,Lal RA,Arbiter B,Brown A,DeSalvo DJ,Pettus J,Calhoun P,Beck RW

    更新日期:2020-11-23 00:00:00

  • Metrics to Evaluate Quality of Glycemic Control: Comparison of Time in Target, Hypoglycemic, and Hyperglycemic Ranges with "Risk Indices".

    abstract:OBJECTIVE:We sought to cross validate several metrics for quality of glycemic control, hypoglycemia, and hyperglycemia. RESEARCH DESIGN AND METHODS:We analyzed the mathematical properties of several metrics for overall glycemic control, and for hypo- and hyperglycemia, to evaluate their similarities, differences, and ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2017.0416

    authors: Rodbard D

    更新日期:2018-05-01 00:00:00